Gastroenterology · UK
IBD biologics: screening and infusion, done properly.
A gastroenterology‑ and nurse‑led private pathway for Crohn’s disease and ulcerative colitis - pre‑biologic screening to BSG standards, infusion delivery in a proper suite, and monitoring that catches loss of response before symptoms return.
Indicative pricing
What a private IBD biologics pathway costs in the UK.
Indicative ranges across our partner infusion suites.
In short
£1,200–£3,200, home the same day.
| Element | Indicative range | Typical duration | Turnaround |
|---|---|---|---|
| Pre‑biologic screening bundle (bloods, TB, CXR) | £450–£900 | 1 visit | 7–10 days |
| IBD consultant review and treatment plan | £300–£500 | 45–60 min | Same visit |
| Infliximab infusion (per dose, drug + chair) | £1,200–£2,800 | 2–3 hrs | Same visit |
| Vedolizumab IV infusion (per dose) | £1,800–£3,200 | 1 hr | Same visit |
| Ustekinumab IV loading + SC maintenance | £2,200–£3,800 | 1–2 hrs | Same visit |
| Risankizumab IV loading course (per dose) | £2,600–£4,200 | 1 hr | Same visit |
| Therapeutic drug monitoring (trough + antibody) | £120–£220 | Blood draw | 5–10 days |
| Quarterly monitoring bloods + calprotectin | £150–£280 | 15 min | 3–5 days |
Prices vary by drug, by whether an originator or biosimilar is used, by the infusion setting, and by your weight (weight‑based doses cost more at 90 kg than at 60 kg).
The problem
The right drug, the right screening, the right infusion setting.
Starting a biologic sounds simple until it isn’t: cut‑corner TB screening, an anonymous chair with no IBD nurse, and no plan for loss of response. We fix all three before the first dose.
-
Not sure which biologic?
Anti‑TNF, vedolizumab, IL‑23, JAK, S1P - the choice depends on your IBD, prior treatment and comorbidities. An IBD consultant frames the trade‑offs honestly.
-
Worried about the risks?
Full BSG‑standard screening, latent TB treated first, Green Book vaccinations up to date, and a plain‑English risk conversation before day one.
-
Want it delivered properly?
A CQC‑registered infusion suite with a specialist IBD nurse, resuscitation cover, therapeutic drug monitoring and MDT follow‑up built in.
When it helps
When a biologic is the right step in IBD.
The clinical situations we see most, plus the red flag that means the same‑day medical review, not the next scheduled dose.
-
Moderate‑to‑severe Crohn’s disease
Active Crohn’s not controlled on 5‑ASA, steroids or thiopurines - the point at which anti‑TNF, vedolizumab, ustekinumab or risankizumab enters the conversation.
-
Moderate‑to‑severe ulcerative colitis
UC failing mesalazine and thiopurines, or steroid‑dependent. Options include infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, mirikizumab, JAK inhibitors and S1P modulators.
-
Steroid‑dependent or steroid‑refractory
Repeat courses of prednisolone are not a maintenance plan. A biologic protects the bowel and gets you off steroids.
-
Perianal or fistulising Crohn’s
Fistulae, abscesses or perianal disease - infliximab remains the workhorse, often with surgical drainage in parallel.
-
Loss of response on current biologic
Symptoms creeping back on a drug that used to work - TDM, dose optimisation, or a switch within or between classes.
-
Acute severe UC after IV steroids
Rescue therapy with infliximab or ciclosporin in hospital, then a maintenance plan on discharge.
-
Pre‑surgery optimisation
Nutrition, iron, steroid weaning and biologic timing coordinated with the colorectal team before an elective bowel resection.
-
Red flag: fever on a biologic
A new fever, cough, night sweats or spreading skin infection on an anti‑TNF or JAK inhibitor is not something to sit on - same‑day medical review.
Therapy options
The full 2026 UK toolkit - and how it fits together.
Each class of biologic and advanced therapy, what it does, and where it sits in the sequencing conversation.
-
Anti‑TNF (infliximab, adalimumab, golimumab)
The original workhorses. Infliximab IV every 8 weeks (or SC), adalimumab SC fortnightly, golimumab SC for UC. Biosimilars widely used - Inflectra, Remsima, Amgevita, Hyrimoz, Yuflyma.
-
Anti‑integrin (vedolizumab)
Gut‑selective - a safer systemic profile than anti‑TNF. IV 30‑minute infusions in the loading phase, then IV every 8 weeks or SC Entyvio Pen maintenance.
-
Anti‑IL‑12/23 and IL‑23 (ustekinumab, risankizumab, mirikizumab)
Weight‑based IV loading dose, then subcutaneous maintenance. Useful when anti‑TNF has failed or is unsuitable. Risankizumab and mirikizumab are the newer IL‑23‑selective options.
-
JAK inhibitors (tofacitinib, upadacitinib)
Oral. Fast onset in UC and Crohn’s, but with a stricter cardiovascular and VZV risk profile - screening and monitoring matter.
-
S1P modulators (ozanimod, etrasimod)
Oral, once daily, for moderate‑to‑severe UC. Cardiac assessment and macular check before starting; slow uptitration in the first week.
-
Thiopurines and methotrexate
Azathioprine or mercaptopurine (TPMT genotype before starting), methotrexate for Crohn’s. Often used alongside anti‑TNF to reduce anti‑drug antibodies.
-
Ciclosporin - acute severe UC rescue
An inpatient alternative to infliximab for steroid‑refractory acute severe UC. Not a maintenance drug; a bridge to a biologic or colectomy.
-
5‑ASA and short‑course steroids
Mesalazine remains first‑line for mild‑to‑moderate UC. Steroids are short‑course only - a bridge, never the destination.
Safety and monitoring
What to plan for - honestly.
Biologics are safe, well‑studied and life‑changing for the right patient. The work is in the screening beforehand, the vaccinations at the right moment, and the monitoring that catches trouble early.
-
Pre‑biologic screening is not optional
TB, hepatitis B and C, HIV, varicella and MMR immunity, EBV, and Green Book vaccinations. Latent TB is treated before an anti‑TNF starts - 9 months isoniazid or 4 months rifampicin per BTS and BSG.
-
Live vaccines before, not during
MMR, varicella, yellow fever, live typhoid - any live vaccine needed goes in before biologics start. Once immunosuppressed, live vaccines are off the menu.
-
Infliximab infusion reactions
Mild reactions in 5–10% (flushing, itch, chest tightness), severe anaphylaxis in under 1%. Higher risk on re‑exposure after a long gap - premedication and slower infusion for at‑risk patients.
-
Injection‑site reactions on SC drugs
Adalimumab, ustekinumab, risankizumab and vedolizumab pens can cause local pain, redness and swelling. Usually mild and self‑limiting; rotate sites and let it warm to room temperature.
-
Skin cancer surveillance
Non‑melanoma skin cancer risk rises on long‑term thiopurines and anti‑TNF. An annual dermatology check is part of the plan, not an afterthought.
-
Therapeutic drug monitoring earns its keep
For anti‑TNF loss of response, a trough level and antibody titre tells you whether to dose‑optimise, switch within class or switch mechanism - NICE‑endorsed and cheaper than switching blind.
-
Seasonal boosters and travel
Annual influenza, pneumococcal, COVID and HPV where indicated. Travel advice at least 6–8 weeks ahead so live vaccines can be planned around the biologic schedule.
-
JAK inhibitors carry their own risks
Cardiovascular events, venous thromboembolism and shingles - more of a concern in over‑65s, smokers, and those with cardiovascular history. A frank risk conversation before starting.
-
Red flags on a biologic
Fever, night sweats, cough, spreading skin infection, jaundice or new neurology - call the IBD team the same day. Do not skip the next dose without advice.
Reading your biologics plan
Your treatment plan in four parts. Read the last one first.
Whichever biologic is chosen, the plan the IBD team sends you keeps to the same shape.
A quiet reminder
Biologics language is precise and can read coldly - we translate it for you.
If you would like us to talk you through the plan before your first dose, just ask.
- 01 Header
Diagnosis, disease activity and drug chosen
Which IBD, current activity score (Harvey‑Bradshaw or partial Mayo), endoscopic and calprotectin findings, and which biologic or advanced therapy is being started.
- 02 Screening
Pre‑biologic screening results
TB (T‑SPOT or QuantiFERON plus CXR), hepatitis B and C, HIV, varicella and MMR serology, EBV, and vaccination status - with any latent TB treatment plan noted.
- 03 Plan
Loading schedule, maintenance and monitoring
Loading doses, maintenance interval, self‑administration training if SC, and the quarterly monitoring bloods and calprotectin schedule.
- 04 Safety net
What to watch for, and who to call
Read this first: infusion reaction symptoms, red flags on treatment, vaccination rules, and the direct number for the IBD nurse and out‑of‑hours cover.
Recognised by major UK insurers
Cover for IBD biologics varies by insurer, by drug and by whether the biologic is being started or continued.
Frequently asked
Everything we get asked about IBD biologics.
Quick answers on screening, drug choice, cost, self‑administration and what to do when a biologic stops working.
-
When are biologics the right step in Crohn’s or ulcerative colitis?
When 5‑ASA, thiopurines or methotrexate have failed, when disease is moderate‑to‑severe from the outset, when you are steroid‑dependent or steroid‑refractory, or when perianal or fistulising Crohn’s is present. A gastroenterologist decides with you, guided by BSG, IBD UK and the relevant NICE technology appraisal.
-
Which biologics and advanced therapies are used in the UK in 2026?
Anti‑TNFs (infliximab, adalimumab, golimumab), the anti‑integrin vedolizumab, the IL‑12/23 and IL‑23 drugs ustekinumab, risankizumab and mirikizumab, JAK inhibitors tofacitinib and upadacitinib, and S1P modulators ozanimod and etrasimod. Filgotinib was withdrawn from the UK in 2024. Each has its own NICE technology appraisal.
-
What screening is needed before starting a biologic?
TB screening (T‑SPOT or QuantiFERON plus a chest X‑ray and a careful history), hepatitis B (surface antigen, core and surface antibody), hepatitis C, HIV, varicella and MMR immunity with catch‑up vaccination if non‑immune, EBV in younger patients, TPMT if a thiopurine is planned, plus the Green Book vaccination schedule for immunosuppression.
-
What happens on infusion day?
You are cannulated, baseline observations are taken, and the drug is given by a specialist nurse over 30 minutes to 2 hours depending on which one. You are observed for 30–60 minutes afterwards (longer for a first infliximab dose), then home the same day with the next appointment booked.
-
What does a private biologics pathway cost?
Roughly £450–£900 for the screening bundle, £300–£500 for the IBD consultant plan, and per‑dose infusion costs from around £1,200 for an infliximab dose to £2,600–£4,200 for a risankizumab loading dose - drug plus chair time. Monitoring bloods and calprotectin sit around £150–£280 per quarter.
-
Are biosimilars as good as the originator?
Yes. UK IBD services routinely use infliximab and adalimumab biosimilars - Inflectra, Remsima, Flixabi and Zessly for infliximab; Amgevita, Hyrimoz and Yuflyma for adalimumab. Efficacy and safety are equivalent, cost is lower, and switching between biosimilars is well studied.
-
What if my drug stops working?
Loss of response is common and manageable. That decision is made in an IBD MDT, not by a single clinician alone.
-
Can I have vaccinations while on a biologic?
Inactivated vaccines yes - annual flu, pneumococcal, COVID and HPV where indicated. Live vaccines (MMR, varicella, yellow fever, live typhoid) should be given before you start, or after a washout if you stop. Travel plans deserve 6–8 weeks’ notice so we can sequence things properly.
-
Can I self‑administer at home?
For adalimumab, ustekinumab (after IV loading), risankizumab maintenance, vedolizumab SC pen and certolizumab - yes, after training with the IBD nurse. Infliximab IV, ustekinumab IV loading and risankizumab IV loading are given in a supervised infusion setting.
-
When should I ring the IBD team urgently?
New fever, night sweats or productive cough, spreading skin infection or shingles, jaundice, new neurological symptoms, or a suspected infusion reaction - same day. Do not miss the next dose without discussing it first.